GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Down 85.0% in August

GlucoTrack, Inc. (NASDAQ:GCTK) saw a significant decrease in short interest in August. As of August 31st, there was short interest totaling 24,951 shares, a decrease of 85.0% from the August 15th total of 165,864 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 207,650 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in GlucoTrack by 102,125.0% in the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after acquiring an additional 4,085 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in GlucoTrack during the 4th quarter valued at about $52,000. Finally, Ikarian Capital LLC acquired a new position in shares of GlucoTrack in the 4th quarter valued at about $177,000. 10.92% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GCTK shares. Wall Street Zen raised GlucoTrack from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GlucoTrack in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

GlucoTrack Stock Down 23.1%

NASDAQ:GCTK traded down $0.75 during trading hours on Friday, hitting $2.48. 607,979 shares of the stock traded hands, compared to its average volume of 399,102. The firm has a 50 day moving average price of $5.44 and a 200 day moving average price of $9.71. The company has a current ratio of 0.46, a quick ratio of 0.46 and a debt-to-equity ratio of 0.08. GlucoTrack has a fifty-two week low of $2.26 and a fifty-two week high of $212.10. The firm has a market cap of $1.76 million, a price-to-earnings ratio of -0.02 and a beta of 0.62.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.